Sotera Health CoSHC
▲ PositiveCapitalrelevance
Beats Q2 estimates and raises full-year guidance.
Impact on stocks 1
Biotech & Genomic Medicine
Sotera Health CoSotera Health Beats Q2 Estimates and Raises Full-Year Guidance
Earnings
Sotera Health Company reported second-quarter revenue of $321.4 million, beating analyst estimates of $309.6 million and growing 9.2% year over year. Adjusted EPS came in at $0.26 versus expectations of $0.24, and adjusted EBITDA reached $165.7 million against a $157.7 million consensus. Management raised full-year revenue guidance to $1.25 billion at the midpoint from $1.24 billion and lifted adjusted EPS guidance to $0.98, a 1% increase. CEO Alton Shader attributed the outperformance to strong demand in Sterigenics and Nordion, improved customer engagement at Nelson Labs, and favorable Cobalt-60 shipment timing. The company also highlighted new X-ray sterilization capacity and a large customer outsourcing sterilization services as catalysts for the second half.
Sotera Health CoBeats Q2 estimates and raises full-year guidance.